Evoke Pharma Inc
EVOK5.039USD
+0.349+7.43%
Horário de mercado （ET）Cotações atrasadas em 15 min
7.52MValor de mercado
PerdaP/L TTM
Mais detalhes de Evoke Pharma Inc Empresa
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
Informações da empresa
Código da empresaEVOK
Nome da EmpresaEvoke Pharma Inc
Data de listagemSep 25, 2013
CEOMr. Matthew J. (Matt) D'Onofrio
Número de funcionários3
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 25
Endereço420 Stevens Avenue
CidadeSOLANA BEACH
Bolsa de valoresLondon Stock Exchange
PaísUnited States of America
Código postal92075
Telefone18583451494
Sitehttps://evokepharma.com/
Código da empresaEVOK
Data de listagemSep 25, 2013
CEOMr. Matthew J. (Matt) D'Onofrio
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Benjamin C. (Ben) Smeal
Mr. Benjamin C. (Ben) Smeal
Independent Director
Independent Director
--
--
Mr. Daniel Kontoh-Boateng
Mr. Daniel Kontoh-Boateng
Investor Contact
Investor Contact
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q1
FY2023
FY2022
FY2021
FY2020
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
3.08M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 24 de mai
Atualizado em: sáb, 24 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Nantahala Capital Management, LLC
9.92%
Bleichroeder LP
4.61%
Citadel Advisors LLC
1.66%
D'Onofrio (Matthew J)
0.66%
Geode Capital Management, L.L.C.
0.53%
Other
82.62%
Investidores
Investidores
Proporção
Nantahala Capital Management, LLC
9.92%
Bleichroeder LP
4.61%
Citadel Advisors LLC
1.66%
D'Onofrio (Matthew J)
0.66%
Geode Capital Management, L.L.C.
0.53%
Other
82.62%
Tipos de investidores
Investidores
Proporção
Hedge Fund
11.60%
Investment Advisor
4.62%
Individual Investor
1.34%
Investment Advisor/Hedge Fund
0.70%
Other
81.74%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
34
272.65K
18.26%
-174.03K
2025Q1
37
273.02K
18.29%
-164.20K
2024Q4
38
286.68K
19.29%
-150.95K
2024Q3
39
276.54K
27.87%
-57.30K
2024Q2
39
330.88K
325.68%
-1.95K
2024Q1
46
331.84K
45.81%
+48.22K
2023Q4
42
12.65K
4.52%
-4.41K
2023Q3
46
12.52K
4.50%
-16.16K
2023Q2
47
11.87K
4.27%
-16.69K
2023Q1
53
12.69K
4.56%
-16.37K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Nantahala Capital Management, LLC
148.15K
9.92%
--
--
Mar 31, 2025
Bleichroeder LP
68.75K
4.61%
--
--
Mar 31, 2025
Citadel Advisors LLC
24.80K
1.66%
+24.80K
--
Mar 31, 2025
D'Onofrio (Matthew J)
9.82K
0.66%
+1.32K
+15.50%
Mar 24, 2025
Geode Capital Management, L.L.C.
7.93K
0.53%
--
--
May 31, 2025
Kowieski (Mark A.)
4.92K
0.33%
+4.92K
--
Mar 24, 2025
The Vanguard Group, Inc.
2.49K
0.17%
--
--
May 31, 2025
Gonyer (David A)
2.36K
0.16%
-1.00
-0.04%
Mar 24, 2025
Garner (Cam L)
2.33K
0.16%
-1.00
-0.04%
Mar 24, 2025
Carlson (Marilyn R.)
360.00
0.02%
--
--
Mar 24, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
May 20, 2022
Merger
12<1
May 20, 2022
Merger
12<1
Data
Tipo
Proporção
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
Jul 30, 2024
Merger
12<1
May 20, 2022
Merger
12<1
May 20, 2022
Merger
12<1
May 20, 2022
Merger
12<1
May 20, 2022
Merger
12<1
